Related Experiment Video

Updated: Feb 26, 2026

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

16.3K

Carrier priming to improve pneumococcal disease control and reduce the international program's cost in children

Mohamed Tashani1,2,3, Harunor Rashid1,2,3,4, Kim Mulholland5,6

  • 1National Centre for Immunisation Research and Surveillance (NCIRS), The Children's Hospital at Westmead, Sydney, NSW Australia.

Pneumonia (Nathan Qld.)
|July 14, 2017
PubMed

Insights

Sequential administration of diphtheria-toxoid-containing vaccines (DTP) before pneumococcal conjugate vaccine (PCV) may enhance PCV immunogenicity. This carrier priming phenomenon could improve vaccine effectiveness and reduce costs in developing nations.

Area of Science:

  • Immunology
  • Vaccinology
  • Public Health

Background:

  • Pneumococcal conjugate vaccines (PCV) may interact with diphtheria toxin-like antigen vaccines (e.g., DTP).
  • This interaction stems from the similarity between diphtheria toxoid and the carrier protein (CRM197) in PCV.

Discussion:

  • Sequential administration, specifically DTP before PCV, can induce "carrier priming."
  • Carrier priming enhances the immunogenicity of PCV due to antigen similarity.

Key Insights:

  • Carrier priming offers a strategy to boost PCV immunogenicity.
  • This phenomenon can potentially reduce the number of PCV doses needed.
  • Enhanced immunogenicity can lead to more cost-effective immunization programs.

Outlook:

  • Implementing carrier priming in immunization schedules could benefit developing countries.
  • Vulnerable populations may experience improved vaccine responses.
  • Further research can optimize sequential vaccination strategies for global health.

Keywords:
Carrier primingPneumococcal conjugate vaccine

More Related Videos

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.7K
Capsular Serotyping of Streptococcus pneumoniae by Latex Agglutination09:11

Capsular Serotyping of Streptococcus pneumoniae by Latex Agglutination

Published on: September 25, 2014

22.7K

Related Concept Videos

Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.7K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
890
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.1K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
3.5K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
407
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
1.0K